Raptor Pharmaceutical Inc.
7 Hamilton Landing
Suite 100
Novato
California
94949
United States
Tel: 415-408-6200
Fax: 415-382-8002
Website: http://raptorpharma.com/
Email: info@raptorpharma.com
188 articles about Raptor Pharmaceutical Inc.
-
BioSpace Movers and Shakers Nov. 5
11/5/2018
Biopharma companies make key appointments to fill leadership positions. Let's take a look! -
AltiBio Announces Closing of Series A Preferred Stock Financing Following Positive Proof of Concept Studies
9/10/2018
Several of the lead investors in this round were also initial investors in both BioMarin Pharmaceutical and Raptor Pharmaceuticals
-
Biotech Movers and Shakers Aug. 27
8/27/2018
Who made a splash in the biotech world this week? Here are some notable people. -
Horizon Pharma Completes Acquisition Of Raptor
10/25/2016
-
Another One Bites the Dust... Horizon Pharma Takes Out Bay Area's Raptor in $800 Million Deal
9/14/2016
-
Raptor Presents Results From Meta-Analysis Demonstrating Efficacy Of QUINSAIR Comparable To Other Approved, Inhaled Antibiotics In Cystic Fibrosis Patients
9/7/2016
-
Raptor To Present Data On QUINSAIR And Other Inhaled Antibiotics At The ERS International Congress
8/24/2016
-
Raptor Voted A “Best Places To Work” Company In The North San Francisco Bay Area
8/19/2016
-
Martin Shkreli's Former Firm Retrophin Considering Acquisition of Bay Area's Raptor, Deal Could be Worth $589 Million+
8/18/2016
-
Raptor Reports Second Quarter 2016 Financial Results
8/5/2016
-
Raptor To Hold Second Quarter 2016 Financial Results Conference Call And Webcast On Thursday, August 4, 2016, At 4:30 P.M. EDT
7/28/2016
-
Raptor Reports First Quarter 2016 Financial Results
5/6/2016
-
Three Big Obstacles Bay Area's Raptor Needs to Overcome
3/22/2016
-
Raptor’s PROCYSBI New Drug Submission Accepted By Health Canada With Priority Review
3/22/2016
-
Raptor To Participate In The Cowen and Company 36th Annual Health Care Conference
3/1/2016
-
Raptor To Participate In International Rare Disease Week Through Multiple Patient Advocacy Activities
2/29/2016
-
BioMarin, Raptor, Buck Institute for Age Research Lead Marin Biotech Boom
12/31/2015
-
Raptor Plans To Advance RP103 In A Registration Study In Huntington's Disease Based On Favorable Treatment Effects At 36 Months In CYST-HD Trial
12/10/2015
-
Raptor Release: NIDDK Provides Additional Data From Cynch Study Evaluating RP103 In Pediatric NASH At American Association for Study of Liver Diseases
11/16/2015
-
Raptor To Hold Third Quarter 2015 Financial Results Conference Call And Webcast On Thursday, November 5, 2015, At 4:30 P.M. ET
10/30/2015